choline has been researched along with Pituitary Neoplasms in 12 studies
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Excerpt | Relevance | Reference |
---|---|---|
"We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer." | 7.83 | Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016) |
"Craniopharyngiomas are rare tumors of low histological malignancy (World Health Organization grade I) in the sellar and suprasellar region of the brain." | 5.72 | 18F-Choline PET Detected the Third Ventricle Craniopharyngioma. ( Lu, X; Wang, Z; Zhang, Y; Zhao, K; Zhu, Y, 2022) |
"We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer." | 3.83 | Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016) |
"Craniopharyngiomas are rare tumors of low histological malignancy (World Health Organization grade I) in the sellar and suprasellar region of the brain." | 1.72 | 18F-Choline PET Detected the Third Ventricle Craniopharyngioma. ( Lu, X; Wang, Z; Zhang, Y; Zhao, K; Zhu, Y, 2022) |
"There were 19 pituitary adenomas, 7 gliomas, 5 craniopharyngiomas, 3 chordomas, meningioma, hemangiopericytoma, malignant lymphoma, germinoma, Rathke cleft cyst, and hypothalamic hamartoma (one of each)." | 1.35 | Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors. ( Amano, K; Chernov, MF; Hori, T; Iseki, H; Kawamata, T; Kubo, O; Muragaki, Y; Nakamura, R; Ono, Y; Suzuki, T; Takakura, K, 2009) |
"Maitotoxin (MTX) is a water-soluble polyether, isolated from the marine dinoflagellate Gambierdiscus toxicus, that stimulates hormone release and Ca2+ influx." | 1.28 | Maitotoxin induces a calcium-dependent membrane depolarization in GH4C1 pituitary cells via activation of type L voltage-dependent calcium channels. ( Ramsdell, JS; Van Dolah, FM; Xi, D, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (25.00) | 18.7374 |
1990's | 3 (25.00) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Zhu, Y | 1 |
Zhao, K | 1 |
Wang, Z | 1 |
Zhang, Y | 1 |
Lu, X | 1 |
Szabo, AK | 2 |
Pesti, K | 2 |
Mike, A | 2 |
Vizi, ES | 2 |
Maffione, AM | 1 |
Mandoliti, G | 1 |
Pasini, F | 1 |
Colletti, PM | 1 |
Rubello, D | 1 |
Chernov, MF | 1 |
Kawamata, T | 1 |
Amano, K | 1 |
Ono, Y | 1 |
Suzuki, T | 1 |
Nakamura, R | 1 |
Muragaki, Y | 1 |
Iseki, H | 1 |
Kubo, O | 1 |
Hori, T | 1 |
Takakura, K | 1 |
Hara, T | 1 |
Kosaka, N | 1 |
Shinoura, N | 1 |
Kondo, T | 1 |
Kinoshita, Y | 1 |
Yokota, A | 1 |
Shimizu, C | 1 |
Yamane, Y | 1 |
Ishizuka, T | 1 |
Kijima, H | 1 |
Takano, K | 1 |
Takano, A | 1 |
Kubo, M | 1 |
Koike, T | 1 |
Xi, D | 1 |
Van Dolah, FM | 1 |
Ramsdell, JS | 1 |
Carmeliet, P | 1 |
Denef, C | 1 |
Kolesnick, RN | 1 |
Jaken, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma[NCT01377220] | Phase 2 | 30 participants (Anticipated) | Interventional | 2011-06-30 | Not yet recruiting | ||
Clinical Value of [18]Fluoroethylcholine Positron-Emission-Tomography Combined With Endorectal Magnetic Resonance Imaging by Software Fusion for Pre-therapeutic Staging of Prostate Cancer[NCT00520546] | Phase 3 | 44 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
PET positive lesions (n=128) were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative and positive predictive values were determined. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
Intervention | lesions (Number) | |||||
---|---|---|---|---|---|---|
True positive | False positive | True negative | False negative | Total true | Total false | |
FEC-PET | 59 | 26 | 19 | 24 | 78 | 50 |
Magnetic Resonance Imaging (MRI) | 40 | 27 | 18 | 43 | 58 | 70 |
PET/MRI | 55 | 8 | 37 | 28 | 92 | 36 |
PET positive lesions in patients with Gleason >6(3+3),n=43 were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative & positive predictive values were determined. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
Intervention | lesions (Number) | |||||
---|---|---|---|---|---|---|
True positive | False positive | True negative | False negative | Total true | Total false | |
FEC-PET | 27 | 5 | 8 | 3 | 35 | 8 |
Magnetic Resonance Imaging (MRI) | 22 | 9 | 4 | 8 | 26 | 17 |
PET/MRI | 27 | 1 | 11 | 4 | 38 | 5 |
PET positive lesions were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative and positive predictive values were determined without malign lesions <=5mm. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
Intervention | lesions (Number) | |||||
---|---|---|---|---|---|---|
True positive | False positive | True negative | False negative | Total true | Total false | |
FEC-PET | 48 | 24 | 18 | 8 | 66 | 32 |
Magnetic Resonance Imaging (MRI) | 37 | 26 | 16 | 19 | 53 | 45 |
PET/MRI | 48 | 8 | 32 | 10 | 80 | 18 |
PET positive lesions were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. At least 1 histological confirmed cancer lesion has to be detected by each of the 3 methods to be patient based true positive. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
True Positive | False Positive | True Negative | False Negative | Total True | Total False | |
[18F]Fluoroethylcholine Positron-Emission-Tomography (FEC-PET) | 36 | 1 | 0 | 1 | 36 | 2 |
Magnetic Resonance Imaging (MRI) | 26 | 1 | 0 | 11 | 27 | 11 |
PositronEmissionTomography/MagneticResonanceImaging (PET/MRI) | 35 | 0 | 1 | 2 | 36 | 2 |
12 other studies available for choline and Pituitary Neoplasms
Article | Year |
---|---|
18F-Choline PET Detected the Third Ventricle Craniopharyngioma.
Topics: Adult; Choline; Contrast Media; Craniopharyngioma; Gadolinium; Humans; Male; Pituitary Neoplasms; Po | 2022 |
Mode of action of the positive modulator PNU-120596 on α7 nicotinic acetylcholine receptors.
Topics: Acetylcholine; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Biophysics; | 2014 |
Kinetic properties and open probability of α7 nicotinic acetylcholine receptors.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Biophysical Phenomena; Cell Line, T | 2014 |
Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse.
Topics: Adenoma; Choline; Humans; Incidental Findings; Male; Middle Aged; Pituitary Neoplasms; Positron Emis | 2016 |
Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors.
Topics: Adult; Aspartic Acid; Astrocytoma; Chi-Square Distribution; Choline; Craniopharyngioma; Creatine; Di | 2009 |
PET imaging of brain tumor with [methyl-11C]choline.
Topics: Adenoma; Aged; Animals; Brain; Brain Neoplasms; Carbon Radioisotopes; Choline; Chromatography, High | 1997 |
PET imaging of brain tumor with [methyl-11C]choline.
Topics: Adenoma; Aged; Animals; Brain; Brain Neoplasms; Carbon Radioisotopes; Choline; Chromatography, High | 1997 |
PET imaging of brain tumor with [methyl-11C]choline.
Topics: Adenoma; Aged; Animals; Brain; Brain Neoplasms; Carbon Radioisotopes; Choline; Chromatography, High | 1997 |
PET imaging of brain tumor with [methyl-11C]choline.
Topics: Adenoma; Aged; Animals; Brain; Brain Neoplasms; Carbon Radioisotopes; Choline; Chromatography, High | 1997 |
Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy.
Topics: Adenoma; Adolescent; Adult; Aged; Amino Acids; Brain; Brain Neoplasms; Child; Choline; Creatine; Fem | 1997 |
Involvement of the cholinergic pathway in the pathogenesis of pituitary Cushing's syndrome.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adenoma; Adrenocorticotropic Hormone; Atropine; Choline; | 2001 |
Maitotoxin induces a calcium-dependent membrane depolarization in GH4C1 pituitary cells via activation of type L voltage-dependent calcium channels.
Topics: Animals; Calcium; Calcium Channels; Cell Membrane; Choline; Dose-Response Relationship, Drug; Isradi | 1992 |
Synthesis and release of acetylcholine by normal and tumoral pituitary corticotrophs.
Topics: Acetylcholine; Adrenocorticotropic Hormone; Animals; Cell Line; Choline; Choline O-Acetyltransferase | 1989 |
1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells.
Topics: Animals; Ceramides; Choline; Diglycerides; Dose-Response Relationship, Drug; Enzyme Activation; Glyc | 1987 |
Increased diacylglycerol content with phospholipase C or hormone treatment: inhibition of phorbol ester binding and induction of phorbol ester-like biological responses.
Topics: Animals; Binding, Competitive; Caenorhabditis elegans Proteins; Carrier Proteins; Cell Line; Choline | 1985 |